<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218734</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC/DBPR108201903/PRO-III-2</org_study_id>
    <nct_id>NCT04218734</nct_id>
  </id_info>
  <brief_title>A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel Controlled Phase III Clinical Trial of DBRP108 in Combination With Metformin Hydrochloride in the Treatment of Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy and safety of DBPR108 tablets in combination with&#xD;
      metformin hydrochloride in the treatment of type 2 diabetes mellitus. A total of 210 subjects&#xD;
      will be randomly assigned in a ratio of 2:1 to receive metformin hydrochloride plus DBPR108&#xD;
      or metformin hydrochloride plus placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Actual">June 3, 2021</completion_date>
  <primary_completion_date type="Actual">June 3, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c (%) from baseline to week 24</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>The change of HbA1c from baseline to 24 weeks compared with metformin hydrochloride + placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of HbA1c ≤ 6.5%</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients achieving HbA1c ≤ 6.5% at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of HbA1c ≤ 7%</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients achieving HbA1c ≤ 7% at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c (%) from baseline to week 12</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The change of HbA1c from baseline to 12 weeks compared with metformin hydrochloride + placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG) from baseline to week 12 and week 24</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks</time_frame>
    <description>The change in FPG from baseline to week 12 and week 24 compared with metformin hydrochloride + placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2h-postprandial plasma glucose (2h-PPG) from baseline to week 12 and week 24</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks</time_frame>
    <description>The change in 2h-PPG from baseline to week 12 and week 24 compared with metformin hydrochloride + placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight from baseline to week 12 and week 24</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks</time_frame>
    <description>The change in body weight from baseline to week 12 and week 24 compared with metformin hydrochloride +placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>metformin hydrochloride+DBPR108</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin hydrochloride 500 mg+DBPR108 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin hydrochloride+placepo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>metformin hydrochloride 500 mg+placebo 100 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DBPR108</intervention_name>
    <description>DBPR108: 100 mg, once daily for 24 weeks.</description>
    <arm_group_label>metformin hydrochloride+DBPR108</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin hydrochloride</intervention_name>
    <description>metformin hydrochloride: 500 mg, 1-3 times daily for 24 weeks.</description>
    <arm_group_label>metformin hydrochloride+DBPR108</arm_group_label>
    <arm_group_label>metformin hydrochloride+placepo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placepo</intervention_name>
    <description>placebo:100 mg, once daily for 24 weeks.</description>
    <arm_group_label>metformin hydrochloride+placepo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of type 2 diabetes according to World Health Organization (1999) diabetes&#xD;
             diagnosis standard;&#xD;
&#xD;
          -  Age 18-75 years, men and women;&#xD;
&#xD;
          -  BMI 19-35 kg/m2;&#xD;
&#xD;
          -  HbA1c 7.0%-9.5%;&#xD;
&#xD;
          -  Before screening, a stable Metformin dose（≥1000mg/day）should be maintained for at&#xD;
             least 8 weeks.&#xD;
&#xD;
          -  Signed informed consent from the patient;&#xD;
&#xD;
          -  Agree to use contraceptive measures from the date of signing the informed consent to 1&#xD;
             month after the end of the last medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  FPG &gt; 13.9 mmol/L;&#xD;
&#xD;
          -  Insulin treatment required in the investigator's opinion;&#xD;
&#xD;
          -  Administration of antidiabetic drugs (except for metformin) including insulin,&#xD;
             rosiglitazone, pioglitazone, DPP-4 inhibitor, Glucagon like peptide-1 (GLP-1) receptor&#xD;
             agonist for 8 weeks before screening;&#xD;
&#xD;
          -  Acute complications of diabetes (including diabetic ketosis and ketoacidosis,&#xD;
             hyperosmotic nonketotic diabetic coma, lactic acidosis and hypoglycemia coma);&#xD;
&#xD;
          -  Severe hypoglycemia;&#xD;
&#xD;
          -  Serious diabetic complications (such as diabetic foot, etc.);&#xD;
&#xD;
          -  History of acute or chronic pancreatitis, or related diseases that are most common&#xD;
             cause of acute pancreatitis (such as recurrent cholelithiasis, etc.);&#xD;
&#xD;
          -  History of being allergic to DPP-4 inhibitors;&#xD;
&#xD;
          -  Untreated hyperthyroidism and other diseases which may cause secondary hyperglycemia;&#xD;
&#xD;
          -  Previous treatment with glucocorticoids (except for external use and inhalation)&#xD;
             within 4 weeks before screening or may be used for more than 14 consecutive days&#xD;
             during the study;&#xD;
&#xD;
          -  Inflammatory bowel disease, partial intestinal obstruction or chronic bowel disease&#xD;
             related to obvious digestive and absorption disorders;&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) &gt; 3*upper limit of&#xD;
             normal (ULN), or total bilirubin &gt; 1.5ULN;&#xD;
&#xD;
          -  Abnormal renal function;&#xD;
&#xD;
          -  White blood cells (WBC) &lt; 3.0109/l, neutrophil count of peripheral blood &lt; 1.5109/l,&#xD;
             hemoglobin &lt; 100g / L, triglyceride &gt; 5.7 mmol/l;&#xD;
&#xD;
          -  HBsAg, HBeAg or HBcAb positive, or any one of hepatitis C antibody, anti-HIV antibody&#xD;
             and nonspecific antibody of Treponema pallidum positive;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  History of alcohol or drug abuse;&#xD;
&#xD;
          -  Participation in other clinical trials or administration of any other investigational&#xD;
             drugs or devices within 3 months before screening;&#xD;
&#xD;
          -  Significant unstable diseases;&#xD;
&#xD;
          -  Any condition that in the investigator's opinion might render the patient unable to&#xD;
             participate the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun Lou</last_name>
    <role>Study Director</role>
    <affiliation>Department of medicine, CSPC clinical development division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DBPR108</keyword>
  <keyword>Dipeptidyl peptidase-4 (DPP4) inhibitors</keyword>
  <keyword>metformin hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

